Invivyd (IVVD) Net Income towards Common Stockholders (2021 - 2025)
Invivyd (IVVD) posted Net Income towards Common Stockholders of -$12.2 million for Q4 2025, down 3.33% on a QoQ basis from -$11.8 million in Q3 2025, and up 33.93% year-over-year from -$9.1 million in Q4 2024.
Invivyd (IVVD) Net Income towards Common Stockholders (2021 - 2025) Analysis & Trends
Invivyd's Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$12.2 million for Q4 2025.
- Quarterly Net Income towards Common Stockholders rose 33.93% year-over-year to -$12.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$56.6 million (up 73.07% YoY) and the FY2025 annual result came in at -$307.8 million, up 26.95% from the prior year.
- Net Income towards Common Stockholders was -$12.2 million for Q4 2025 at Invivyd, down from -$11.8 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$11.8 million in Q3 2025 and bottomed at -$111.3 million in Q1 2022.
- A 5-year average of -$49.1 million and a median of -$49.0 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 186.87% — and 2025, when it soared 81.12%.
- Invivyd's Net Income towards Common Stockholders stood at -$83.3 million in 2021, then soared by 41.88% to -$48.4 million in 2022, then tumbled by 57.51% to -$76.3 million in 2023, then jumped by 75.71% to -$18.5 million in 2024, then soared by 33.93% to -$12.2 million in 2025.
- Business Quant data shows IVVD's Net Income towards Common Stockholders at -$12.2 million in Q4 2025, -$11.8 million in Q3 2025, and -$15.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Invivyd | 104.07 Mn | -122.62 Mn | 16.07 Mn | -12.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12.24 Mn |
| Sep 30, 2025 | -11.85 Mn |
| Jun 30, 2025 | -15.42 Mn |
| Mar 31, 2025 | -17.12 Mn |
| Dec 31, 2024 | -18.53 Mn |
| Sep 30, 2024 | -62.75 Mn |
| Jun 30, 2024 | -49.68 Mn |
| Mar 31, 2024 | -79.34 Mn |
| Dec 31, 2023 | -76.26 Mn |
| Sep 30, 2023 | -45.04 Mn |
| Jun 30, 2023 | -54.31 Mn |
| Mar 31, 2023 | -39.78 Mn |
| Dec 31, 2022 | -48.41 Mn |
| Sep 30, 2022 | -53.46 Mn |
| Jun 30, 2022 | -58.72 Mn |
| Mar 31, 2022 | -111.33 Mn |
| Dec 31, 2021 | -83.29 Mn |
| Sep 30, 2021 | -60.38 Mn |
| Jun 30, 2021 | -44.67 Mn |
| Mar 31, 2021 | -38.81 Mn |